Health
Medical
Biotechnology

bluebird bio

$149.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.06 (2.09%) Today
+$3.06 (2.09%) Today

Why Robinhood?

You can buy or sell bluebird bio and other stocks, options, ETFs, and crypto commission-free!

About

bluebird bio, Inc. Common Stock, also called bluebird bio, is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Read More Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Employees
764
Headquarters
Cambridge, Massachusetts
Founded
1992
Market Cap
8.00B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
725.01K
High Today
$150.54
Low Today
$146.63
Open Price
$148.07
Volume
86.13K
52 Week High
$199.70
52 Week Low
$87.49

Collections

Health
Medical
Biotechnology
Cancer Prevention
Gene Therapies
Technology
Therapy
2013 IPO

News

Associated Press16h

bluebird bio Statement on European Regulatory Status of LentiGlobin™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 25, 2019--A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has bee...

29
Simply Wall StMar 21

Is bluebird bio, Inc.’s (NASDAQ:BLUE) CEO Salary Justified?

Nick Leschly became the CEO of bluebird bio, Inc. (NASDAQ:BLUE) in 2010. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the growth in the business. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels. Check out our latest analysis for bluebird bio How Does Nick Leschly’s Compensatio...

83
The Motley FoolMar 11

Here's Why bluebird bio Gained 16.3% in February

What happened Shares of bluebird bio (NASDAQ:BLUE) rose over 16% last month, according to data from S&P Global Market Intelligence. The biopharma reported fourth-quarter and full-year 2018 operating results. As a pre-commercial company, there wasn't much in the way of financial numbers to review, although the business did begin 2019 with $1.9 billion in cash, cash equivalents, and marketable securities. Investors were more excited about the update on the company's late-stage pipeline. CEO Nick Leschly sai...

323

Earnings

-$2.91
-$2.49
-$2.08
-$1.66
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.